| Spironolactone for heart failure with preserved ejection fraction B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ... New England Journal of Medicine 370 (15), 1383-1392, 2014 | 2597 | 2014 |
| Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) IS Anand, LD Fisher, YT Chiang, R Latini, S Masson, AP Maggioni, ... Circulation 107 (9), 1278-1283, 2003 | 1185 | 2003 |
| Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures MR Zile, TD Bennett, M St. John Sutton, YK Cho, PB Adamson, MF Aaron, ... Circulation 118 (14), 1433-1441, 2008 | 984* | 2008 |
| Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ... Circulation 131 (1), 34-42, 2015 | 937 | 2015 |
| Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure R Latini, S Masson, IS Anand, E Missov, M Carlson, T Vago, L Angelici, ... Circulation 116 (11), 1242-1249, 2007 | 868 | 2007 |
| Consensus recommendations for the management of chronic heart failure: Introduction M Packer, JN Cohn, WT Abraham, WS Colucci, MB Fowler, BH Greenberg, ... American Journal of Cardiology 83 (2 A), 1A-38A, 1999 | 701 | 1999 |
| Treatment of anemia with darbepoetin alfa in systolic heart failure K Swedberg, JB Young, IS Anand, S Cheng, AS Desai, R Diaz, ... New England Journal of Medicine 368 (13), 1210-1219, 2013 | 652 | 2013 |
| C-reactive protein in heart failure: prognostic value and the effect of valsartan IS Anand, R Latini, VG Florea, MA Kuskowski, T Rector, S Masson, ... Circulation 112 (10), 1428-1434, 2005 | 609 | 2005 |
| Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan … S Masson, R Latini, IS Anand, T Vago, L Angelici, S Barlera, ED Missov, ... Clinical chemistry 52 (8), 1528-1538, 2006 | 531 | 2006 |
| Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, L Liu, B Pitt, ... Circulation 132 (5), 402-414, 2015 | 459 | 2015 |
| Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. IS Anand, R Ferrari, GS Kalra, PL Wahi, PA Poole-Wilson, PC Harris Circulation 80 (2), 299-305, 1989 | 454 | 1989 |
| Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) S Masson, R Latini, IS Anand, S Barlera, L Angelici, T Vago, G Tognoni, ... Journal of the American College of Cardiology 52 (12), 997-1003, 2008 | 442 | 2008 |
| Anemia and chronic heart failure: implications and treatment options IS Anand Journal of the American College of Cardiology 52 (7), 501-511, 2008 | 436 | 2008 |
| Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT IS Anand, MA Kuskowski, TS Rector, VG Florea, RD Glazer, A Hester, ... Circulation 112 (8), 1121-1127, 2005 | 426 | 2005 |
| Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. IS Anand, Y Chandrashekhar, R Ferrari, PA Poole-Wilson, PC Harris Heart 70 (4), 357-362, 1993 | 400 | 1993 |
| Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial RK Premchand, K Sharma, S Mittal, R Monteiro, S Dixit, I Libbus, ... Journal of cardiac failure 20 (11), 808-816, 2014 | 378 | 2014 |
| Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial IS Anand, T Kempf, TS Rector, H Tapken, T Allhoff, F Jantzen, ... Circulation 122 (14), 1387-1395, 2010 | 375 | 2010 |
| Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved … M Haass, DW Kitzman, IS Anand, A Miller, MR Zile, BM Massie, ... Circulation: Heart Failure 4 (3), 324-331, 2011 | 361 | 2011 |
| Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial SD Solomon, AR Rizkala, J Gong, W Wang, IS Anand, J Ge, CSP Lam, ... JACC: Heart Failure 5 (7), 471-482, 2017 | 360 | 2017 |
| Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia JK Ghali, IS Anand, WT Abraham, GC Fonarow, B Greenberg, H Krum, ... Circulation 117 (4), 526-535, 2008 | 357 | 2008 |
Scott SolomonBrigham and Women's HospitalVerified email at rics.bwh.harvard.edu
